In QQ3 2024 (quarter ended 2024-06-30), Anavex Life Sciences reported a net loss of $12.214 million and earnings per share of $-0.14, with no revenue disclosed for the quarter. Operating expenses totaled $14.729 million, driven largely by R&D spend of $11.87 million and G&A of $2.859 million. Depreciation and amortization amounted to $14.203 million, contributing to an EBITDA of $-12.268 million and an operating loss of $14.729 million. Despite the cash burn, the company retains a robust liquidity position, ending the period with $138.756 million in cash and equivalents and no long-term debt, yielding a net cash position of $138.756 million. Total assets stood at $141.535 million with stockholders’ equity of $129.781 million, while retained earnings totaled $(324.451) million, reflecting a substantial accumulated deficit typical of a late-stage clinical-stage biotech prior to commercial revenue.